Article
Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Gastroenterology - 1 Jun 2015
Chalabi-Dchar Mounira, Cassant-Sourdy Stéphanie, Duluc Camille, Fanjul Marjorie, Lulka Hubert, Samain Rémi, Roche Catherine, Breibach Florence, Delisle Marie-Bernadette, Poupot Mary, Dufresne Marlène, Shimaoka Takeshi, Yonehara Shin, Mathonnet Muriel, Pyronnet Stéphane, Bousquet Corinne
Abstract excerpt
BACKGROUND & AIMS: The KRAS gene is mutated in most pancreatic ductal adenocarcinomas (PDAC). Expression of this KRAS oncoprotein in mice is sufficient to initiate carcinogenesis but not progression to cancer. Activation of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) is required for KRAS for induction and maintenance of PDAC in mice. The somatostatin receptor subtype 2 (sst2) inhibits PI3K, but sst2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.